Advertisement

Topics

LabCorp to acquire Chiltern for $1.2B in cash

11:13 EDT 31 Jul 2017 | CentreWatch

LabCorp, a global life sciences company, and Chiltern, a specialty CRO, announced that LabCorp will acquire Chiltern pursuant to a definitive agreement with Chiltern’s shareholders in an all-cash transaction valued at approximately $1.2 billion. Once the transaction is complete, Chiltern will become part of LabCorp’s Covance segment. “This acquisition strengthens our position as a leading […]

The post LabCorp to acquire Chiltern for $1.2B in cash appeared first on CenterWatch News Online.

Original Article: LabCorp to acquire Chiltern for $1.2B in cash

NEXT ARTICLE

More From BioPortfolio on "LabCorp to acquire Chiltern for $1.2B in cash"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...